Skip to main content
Clinical Trials/NCT00473265
NCT00473265
Completed
Phase 2

Bone Properties in Hypoparathyroidism: Effects of PTH

John P. Bilezikian1 site in 1 country68 target enrollmentMay 2004
InterventionsPTH
DrugsPTH

Overview

Phase
Phase 2
Intervention
PTH
Conditions
Hypoparathyroidism
Sponsor
John P. Bilezikian
Enrollment
68
Locations
1
Primary Endpoint
Requirements for Calcium Supplementation
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Whereas much information is known about the properties of bone in primary hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The purpose of this research project is to test the hypothesis that the skeleton in hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and microarchitectural features. We will also test the hypothesis that the skeleton is dependent upon PTH for normal structure and function. Using non-invasive approaches as well as direct analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized. With each patient serving as his/her own control, we will determine how, to what extent, and in what ways the administration of PTH restores skeletal dynamics and structure to the hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH action on bone gained by our many years of studying PTH overexpression in primary hyperparathyroidism. This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis.

Detailed Description

A detailed description of the methods used in this study include the following: direct analysis of bone itself. skeletal dynamics and structure such as dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy.

Registry
clinicaltrials.gov
Start Date
May 2004
End Date
June 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
John P. Bilezikian
Responsible Party
Sponsor Investigator
Principal Investigator

John P. Bilezikian

Dorothy L. and Daniel H. Silberberg Professor of Medicine and Pharmacology

Columbia University

Eligibility Criteria

Inclusion Criteria

  • Hypoparathyroidism

Exclusion Criteria

  • Bisphosphonate use

Arms & Interventions

PTH(1-84)

100mcg of PTH1-84 every other day, every day, or every three days

Intervention: PTH

Outcomes

Primary Outcomes

Requirements for Calcium Supplementation

Time Frame: 2 years

Serum and urinary calcium levels maintained by change in requirements for calcium supplementation

Secondary Outcomes

  • Percent Change in BMD From Baseline to 24 Months by DXA(baseline versus 24 months)
  • Trabecular Width(baseline versus two years)
  • Trabecular Number(baseline versus two years)
  • Cortical Porosity(baseline versus two years)
  • Mineralizing Surface(baseline versus one year)

Study Sites (1)

Loading locations...

Similar Trials